|
Another SGLT-2 inhibitor shows cardiovascular benefit in diabetics
|
6
|
Resverlogix Corp.
|
Jun 12, 2017 07:36PM
|
|
Re: Positives & negatives
|
6
|
Resverlogix Corp.
|
Sep 16, 2015 02:36PM
|
|
We are now 12 months into BETonMACE dosing!
|
6
|
Resverlogix Corp.
|
Nov 11, 2016 12:09PM
|
|
Re: Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
|
6
|
Resverlogix Corp.
|
Jul 08, 2019 12:37PM
|
|
Re: What impact would a PR like this have?
|
6
|
Resverlogix Corp.
|
Jan 28, 2019 11:33PM
|
|
Re: Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018
|
6
|
Resverlogix Corp.
|
Aug 28, 2018 02:49PM
|
|
Zenith Epigenetics Announces Publication of Covalent Bromodomain Inhibitors, Offering a Novel Approach to Targeting BET Bromodomains
|
6
|
Zenith Epigenetics
|
Oct 01, 2018 09:43AM
|
|
Re: Epigenetic Therapeutic Targets Virtual Summit Presentation July 28, 2020
|
6
|
Resverlogix Corp.
|
Jul 29, 2020 10:06AM
|
|
BD-2 selective bromodomain inhibitors
|
6
|
Resverlogix Corp.
|
Sep 15, 2018 10:58AM
|
|
Re: Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
|
6
|
Resverlogix Corp.
|
Sep 07, 2017 11:48AM
|
|
Re: The last DSMB update of Feb 26th....
|
6
|
Resverlogix Corp.
|
Jun 26, 2018 07:09PM
|
|
CANTOS good, but FDA not on board with sub-group analysis
|
6
|
Resverlogix Corp.
|
Oct 18, 2018 02:03PM
|
|
Re: Apabetalone......a Calculated Risk
|
6
|
Resverlogix Corp.
|
Apr 09, 2019 08:34AM
|
|
Re: RVX Current Status
|
6
|
Resverlogix Corp.
|
Feb 27, 2020 09:00AM
|
|
Re: 2% market penetration
|
6
|
Resverlogix Corp.
|
Nov 17, 2017 05:25PM
|
|
Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
|
6
|
Resverlogix Corp.
|
Dec 02, 2019 12:39PM
|
|
Re: Thinking back on an older discussion and wishing we had an update - Few items
|
6
|
Resverlogix Corp.
|
Jul 29, 2020 10:26AM
|
|
Re: Clarification received...
|
6
|
Resverlogix Corp.
|
Jun 09, 2018 11:55AM
|
|
Resverlogix Provides Update on BETonMACE Phase 3 Trial
|
6
|
Resverlogix Corp.
|
Sep 16, 2019 08:44AM
|
|
Re: Zenith Updates
|
6
|
Zenith Epigenetics
|
Jan 29, 2016 12:50PM
|
